

Anil K Sood

List of Publications by Citations

Source: <https://exaly.com/author-pdf/9212491/anil-k-sood-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

333
papers

26,510
citations

75
h-index

157
g-index

391
ext. papers

31,590
ext. citations

9.1
avg, IF

6.83
L-index

#	Paper	IF	Citations
333	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016 , 12, 1-222	10.2	3838
332	Guidelines for the use and interpretation of assays for monitoring autophagy. <i>Autophagy</i> , 2012 , 8, 445-544	10.2	2783
331	Advances and Challenges of Liposome Assisted Drug Delivery. <i>Frontiers in Pharmacology</i> , 2015 , 6, 286	5.6	1103
330	Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. <i>Nature Medicine</i> , 2006 , 12, 939-44	50.5	836
329	Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. <i>Cancer Research</i> , 2005 , 65, 6910-8	10.1	560
328	Paraneoplastic thrombocytosis in ovarian cancer. <i>New England Journal of Medicine</i> , 2012 , 366, 610-8	59.2	505
327	Comprehensive Genomic Characterization of Long Non-coding RNAs across Human Cancers. <i>Cancer Cell</i> , 2015 , 28, 529-540	24.3	465
326	Ovarian cancer. <i>Nature Reviews Disease Primers</i> , 2016 , 2, 16061	51.1	420
325	miRNA Deregulation in Cancer Cells and the Tumor Microenvironment. <i>Cancer Discovery</i> , 2016 , 6, 235-46	24.4	404
324	Stress hormone-mediated invasion of ovarian cancer cells. <i>Clinical Cancer Research</i> , 2006 , 12, 369-75	12.9	374
323	Preclinical and clinical development of siRNA-based therapeutics. <i>Advanced Drug Delivery Reviews</i> , 2015 , 87, 108-19	18.5	313
322	Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. <i>Cancer Cell</i> , 2013 , 23, 186-99	24.3	305
321	Tumour angiogenesis regulation by the miR-200 family. <i>Nature Communications</i> , 2013 , 4, 2427	17.4	295
320	Regulation of tumor angiogenesis by EZH2. <i>Cancer Cell</i> , 2010 , 18, 185-97	24.3	290
319	Sympathetic nervous system regulation of the tumour microenvironment. <i>Nature Reviews Cancer</i> , 2015 , 15, 563-72	31.3	284
318	A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. <i>Cancer Cell</i> , 2018 , 33, 690-705.e9	24.3	277
317	miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2. <i>Nature</i> , 2014 , 512, 431-5	50.4	276

316	microRNA Therapeutics in Cancer - An Emerging Concept. <i>EBioMedicine</i> , 2016 , 12, 34-42	8.8	275
315	Liposomal siRNA nanocarriers for cancer therapy. <i>Advanced Drug Delivery Reviews</i> , 2014 , 66, 110-6	18.5	274
314	Circular RNAs in Cancer. <i>Molecular Therapy - Nucleic Acids</i> , 2019 , 16, 118-129	10.7	225
313	Targeted gene silencing using RGD-labeled chitosan nanoparticles. <i>Clinical Cancer Research</i> , 2010 , 16, 3910-22	12.9	218
312	Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion. <i>American Journal of Pathology</i> , 2004 , 165, 1087-95	5.8	209
311	Hematogenous metastasis of ovarian cancer: rethinking mode of spread. <i>Cancer Cell</i> , 2014 , 26, 77-91	24.3	203
310	The Platelet Lifeline to Cancer: Challenges and Opportunities. <i>Cancer Cell</i> , 2018 , 33, 965-983	24.3	202
309	Social support, psychological distress, and natural killer cell activity in ovarian cancer. <i>Journal of Clinical Oncology</i> , 2005 , 23, 7105-13	2.2	199
308	Platelets and cancer: a casual or causal relationship: revisited. <i>Cancer and Metastasis Reviews</i> , 2014 , 33, 231-69	9.6	195
307	Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. <i>Journal of Clinical Investigation</i> , 2010 , 120, 1515-23	15.9	192
306	RNAi therapies: drugging the undruggable. <i>Science Translational Medicine</i> , 2014 , 6, 240ps7	17.5	176
305	Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER. <i>Nature Communications</i> , 2014 , 5, 5203	17.4	164
304	A novel platform for detection of CK+ and CK- CTCs. <i>Cancer Discovery</i> , 2011 , 1, 580-6	24.4	162
303	Psychosocial factors and interleukin-6 among women with advanced ovarian cancer. <i>Cancer</i> , 2005 , 104, 305-13	6.4	159
302	Platelets increase the proliferation of ovarian cancer cells. <i>Blood</i> , 2012 , 120, 4869-72	2.2	157
301	Reduced adenosine-to-inosine miR-455-5p editing promotes melanoma growth and metastasis. <i>Nature Cell Biology</i> , 2015 , 17, 311-21	23.4	155
300	TP53 loss creates therapeutic vulnerability in colorectal cancer. <i>Nature</i> , 2015 , 520, 697-701	50.4	154
299	Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context. <i>Cell Reports</i> , 2018 , 23, 297-312.e12	10.6	147

298	exRNA Atlas Analysis Reveals Distinct Extracellular RNA Cargo Types and Their Carriers Present across Human Biofluids. <i>Cell</i> , 2019 , 177, 463-477.e15	56.2	144
297	Small RNA Sequencing across Diverse Biofluids Identifies Optimal Methods for exRNA Isolation. <i>Cell</i> , 2019 , 177, 446-462.e16	56.2	142
296	Exploring and comparing adverse events between PARP inhibitors. <i>Lancet Oncology</i> , 2019 , 20, e15-e287	28.7	138
295	Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression. <i>Nature Communications</i> , 2014 , 5, 5202	17.4	130
294	Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer. <i>Cancer</i> , 2015 , 121, 3444-51	6.4	129
293	Social isolation is associated with elevated tumor norepinephrine in ovarian carcinoma patients. <i>Brain, Behavior, and Immunity</i> , 2011 , 25, 250-5	16.6	128
292	Vascular endothelial growth factor and social support in patients with ovarian carcinoma. <i>Cancer</i> , 2002 , 95, 808-15	6.4	128
291	miR-205 acts as a tumour radiosensitizer by targeting ZEB1 and Ubc13. <i>Nature Communications</i> , 2014 , 5, 5671	17.4	125
290	Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma. <i>Journal of the National Cancer Institute</i> , 2014 , 106,	9.7	124
289	Patterns of metastasis in sex cord-stromal tumors of the ovary: can routine staging lymphadenectomy be omitted?. <i>Gynecologic Oncology</i> , 2009 , 113, 86-90	4.9	124
288	Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment. <i>Cancer Discovery</i> , 2013 , 3, 1302-15	24.4	123
287	RNA interference-based therapy and its delivery systems. <i>Cancer and Metastasis Reviews</i> , 2018 , 37, 107-124	124	120
286	Social influences on clinical outcomes of patients with ovarian cancer. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2885-90	2.2	119
285	Autocrine effects of tumor-derived complement. <i>Cell Reports</i> , 2014 , 6, 1085-1095	10.6	118
284	Depression, social support, and beta-adrenergic transcription control in human ovarian cancer. <i>Brain, Behavior, and Immunity</i> , 2009 , 23, 176-83	16.6	118
283	Molecular pathways: translational and therapeutic implications of the Notch signaling pathway in cancer. <i>Clinical Cancer Research</i> , 2015 , 21, 955-61	12.9	115
282	Platelets reduce anoikis and promote metastasis by activating YAP1 signaling. <i>Nature Communications</i> , 2017 , 8, 310	17.4	112
281	Biobehavioral influences on matrix metalloproteinase expression in ovarian carcinoma. <i>Clinical Cancer Research</i> , 2008 , 14, 6839-46	12.9	112

280	RNA-targeted therapeutics in cancer clinical trials: Current status and future directions. <i>Cancer Treatment Reviews</i> , 2016 , 50, 35-47	14.4	110
279	Therapeutic Targeting of ATP7B in Ovarian Carcinoma. <i>Clinical Cancer Research</i> , 2009 , 15, 3770-80	12.9	103
278	Systematic characterization of A-to-I RNA editing hotspots in microRNAs across human cancers. <i>Genome Research</i> , 2017 , 27, 1112-1125	9.7	100
277	Functional significance of VEGFR-2 on ovarian cancer cells. <i>International Journal of Cancer</i> , 2009 , 124, 1045-53	7.5	100
276	Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer. <i>EBioMedicine</i> , 2018 , 38, 100-112	8.8	100
275	A framework for a personalized surgical approach to ovarian cancer. <i>Nature Reviews Clinical Oncology</i> , 2015 , 12, 239-45	19.4	98
274	Platelet "first responders" in wound response, cancer, and metastasis. <i>Cancer and Metastasis Reviews</i> , 2017 , 36, 199-213	9.6	98
273	Mechanisms of nuclear content loading to exosomes. <i>Science Advances</i> , 2019 , 5, eaax8849	14.3	98
272	The role of long noncoding RNAs in cancer: the dark matter matters. <i>Current Opinion in Genetics and Development</i> , 2018 , 48, 8-15	4.9	96
271	Salt-Inducible Kinase 2 Couples Ovarian Cancer Cell Metabolism with Survival at the Adipocyte-Rich Metastatic Niche. <i>Cancer Cell</i> , 2016 , 30, 273-289	24.3	92
270	BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer. <i>Cancer Research</i> , 2016 , 76, 6320-6330	10.1	85
269	Functional role of matrix metalloproteinases in ovarian tumor cell plasticity. <i>American Journal of Obstetrics and Gynecology</i> , 2004 , 190, 899-909	6.4	84
268	A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer. <i>Nature Communications</i> , 2016 , 7, 11169	17.4	83
267	FABP4 as a key determinant of metastatic potential of ovarian cancer. <i>Nature Communications</i> , 2018 , 9, 2923	17.4	82
266	2QOMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. <i>Nature Communications</i> , 2014 , 5, 3459	17.4	81
265	Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers. <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9.7	80
264	Yes-associated protein 1 and transcriptional coactivator with PDZ-binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinoma. <i>Hepatology</i> , 2016 , 63, 159-72	11.2	80
263	Calcium-dependent FAK/CREB/TNNC1 signalling mediates the effect of stromal MFAP5 on ovarian cancer metastatic potential. <i>Nature Communications</i> , 2014 , 5, 5092	17.4	79

262	The clinical significance of tumor cell-lined vasculature in ovarian carcinoma: implications for anti-vasculogenic therapy. <i>Cancer Biology and Therapy</i> , 2002 , 1, 661-4	4.6	79
261	Integrated Analysis of Genetic Ancestry and Genomic Alterations across Cancers. <i>Cancer Cell</i> , 2018 , 34, 549-560.e9	24.3	78
260	Metabolic Markers and Statistical Prediction of Serous Ovarian Cancer Aggressiveness by Ambient Ionization Mass Spectrometry Imaging. <i>Cancer Research</i> , 2017 , 77, 2903-2913	10.1	77
259	MYC Targeted Long Noncoding RNA DANCR Promotes Cancer in Part by Reducing p21 Levels. <i>Cancer Research</i> , 2018 , 78, 64-74	10.1	76
258	Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis. <i>Cell Reports</i> , 2015 , 13, 2395-2402	10.6	75
257	EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma. <i>Journal of the National Cancer Institute</i> , 2009 , 101, 1193-205	9.7	75
256	Antivasular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors. <i>Clinical Cancer Research</i> , 2005 , 11, 4923-33	12.9	74
255	The RNA-binding protein DDX1 promotes primary microRNA maturation and inhibits ovarian tumor progression. <i>Cell Reports</i> , 2014 , 8, 1447-60	10.6	71
254	Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance. <i>Journal of Clinical Investigation</i> , 2018 , 128, 589-606	15.9	71
253	Targeting the tumour microenvironment in ovarian cancer. <i>European Journal of Cancer</i> , 2016 , 56, 131-143	7.5	69
252	Targeting c-MYC in Platinum-Resistant Ovarian Cancer. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 2260-9	6.1	68
251	Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors. <i>Gynecologic Oncology</i> , 2009 , 114, 431-6	4.9	68
250	FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal. <i>Journal of Clinical Investigation</i> , 2016 , 126, 1885-96	15.9	68
249	MiR-101 suppresses the epithelial-to-mesenchymal transition by targeting ZEB1 and ZEB2 in ovarian carcinoma. <i>Oncology Reports</i> , 2014 , 31, 2021-8	3.5	65
248	Differentiation therapy for hepatocellular carcinoma: Multifaceted effects of miR-148a on tumor growth and phenotype and liver fibrosis. <i>Hepatology</i> , 2016 , 63, 864-79	11.2	63
247	Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with Eblockers. <i>Science Translational Medicine</i> , 2017 , 9,	17.5	62
246	Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA). <i>Molecular Cancer Therapeutics</i> , 2017 , 16, 1114-1123	6.1	61
245	Evoking picomolar binding in RNA by a single phosphorodithioate linkage. <i>Nucleic Acids Research</i> , 2016 , 44, 8052-64	20.1	61

244	Erythropoietin Stimulates Tumor Growth via EphB4. <i>Cancer Cell</i> , 2015 , 28, 610-622	24.3	60
243	Therapeutic silencing of KRAS using systemically delivered siRNAs. <i>Molecular Cancer Therapeutics</i> , 2014 , 13, 2876-85	6.1	59
242	Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: Time to incorporate laparoscopic assessment into the standard of care. <i>Gynecologic Oncology</i> , 2015 , 137, 553-8	4.9	56
241	Differential platelet levels affect response to taxane-based therapy in ovarian cancer. <i>Clinical Cancer Research</i> , 2015 , 21, 602-10	12.9	56
240	Adrenergic regulation of monocyte chemotactic protein 1 leads to enhanced macrophage recruitment and ovarian carcinoma growth. <i>Oncotarget</i> , 2015 , 6, 4266-73	3.3	56
239	Direct Upregulation of STAT3 by MicroRNA-551b-3p Deregulates Growth and Metastasis of Ovarian Cancer. <i>Cell Reports</i> , 2016 , 15, 1493-1504	10.6	56
238	Molecular biomarkers of residual disease after surgical debulking of high-grade serous ovarian cancer. <i>Clinical Cancer Research</i> , 2014 , 20, 3280-8	12.9	55
237	Nanotechnology: Future of Oncotherapy. <i>Clinical Cancer Research</i> , 2015 , 21, 3121-30	12.9	54
236	CD44-Targeting PLGA Nanoparticles Incorporating Paclitaxel and FAK siRNA Overcome Chemoresistance in Epithelial Ovarian Cancer. <i>Cancer Research</i> , 2018 , 78, 6247-6256	10.1	53
235	Characteristics of 10-year survivors of high-grade serous ovarian carcinoma. <i>Gynecologic Oncology</i> , 2016 , 141, 260-263	4.9	53
234	Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression. <i>Clinical Cancer Research</i> , 2017 , 23, 7034-7046	12.9	52
233	Notch3 pathway alterations in ovarian cancer. <i>Cancer Research</i> , 2014 , 74, 3282-93	10.1	51
232	Rac1/Pak1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2015 , 21, 2127-37	12.9	49
231	Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer. <i>Oncotarget</i> , 2016 , 7, 15093-15104	3.5	49
230	Performance of the MasSpec Pen for Rapid Diagnosis of Ovarian Cancer. <i>Clinical Chemistry</i> , 2019 , 65, 674-683	5.5	48
229	Definition of PKC- ζ CDK6, and MET as therapeutic targets in triple-negative breast cancer. <i>Cancer Research</i> , 2014 , 74, 4822-35	10.1	48
228	Adrenergic Stimulation of DUSP1 Impairs Chemotherapy Response in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 1713-24	12.9	47
227	Dual targeting of EphA2 and FAK in ovarian carcinoma. <i>Cancer Biology and Therapy</i> , 2009 , 8, 1027-34	4.6	47

226	Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy. <i>Future Oncology</i> , 2016 , 12, 1439-56	3.6	47
225	RNA nanoparticles harboring annexin A2 aptamer can target ovarian cancer for tumor-specific doxorubicin delivery. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2017 , 13, 1183-1193	6	46
224	Sustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction. <i>Cancer Research</i> , 2018 , 78, 3233-3242	10.1	46
223	Activation of YAP1 is associated with poor prognosis and response to taxanes in ovarian cancer. <i>Anticancer Research</i> , 2014 , 34, 811-817	2.3	46
222	Bone protection by inhibition of microRNA-182. <i>Nature Communications</i> , 2018 , 9, 4108	17.4	45
221	Complement Component 3 Is Regulated by TWIST1 and Mediates Epithelial-Mesenchymal Transition. <i>Journal of Immunology</i> , 2016 , 196, 1412-8	5.3	44
220	Therapeutic Targeting of AXL Receptor Tyrosine Kinase Inhibits Tumor Growth and Intraperitoneal Metastasis in Ovarian Cancer Models. <i>Molecular Therapy - Nucleic Acids</i> , 2017 , 9, 251-262	10.7	44
219	Estrogen receptor expression and increased risk of lymphovascular space invasion in high-grade serous ovarian carcinoma. <i>Gynecologic Oncology</i> , 2014 , 133, 473-9	4.9	44
218	Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer. <i>Clinical Cancer Research</i> , 2015 , 21, 448-59	12.9	43
217	PRKCI promotes immune suppression in ovarian cancer. <i>Genes and Development</i> , 2017 , 31, 1109-1121	12.6	43
216	In vivo stepwise immunomodulation using chitosan nanoparticles as a platform nanotechnology for cancer immunotherapy. <i>Scientific Reports</i> , 2016 , 6, 38348	4.9	43
215	LPA Induces Metabolic Reprogramming in Ovarian Cancer via a Pseudohypoxic Response. <i>Cancer Research</i> , 2018 , 78, 1923-1934	10.1	42
214	Immune cell profiling in cancer: molecular approaches to cell-specific identification. <i>Npj Precision Oncology</i> , 2017 , 1, 26	9.8	42
213	Electron cryotomography reveals ultrastructure alterations in platelets from patients with ovarian cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, 14266-71	11.5	41
212	Calcium-mediated oxidative stress: a common mechanism in tight junction disruption by different types of cellular stress. <i>Biochemical Journal</i> , 2017 , 474, 731-749	3.8	40
211	Platelet effects on ovarian cancer. <i>Seminars in Oncology</i> , 2014 , 41, 378-84	5.5	40
210	Perioperative inhibition of Adrenergic and COX2 signaling in a clinical trial in breast cancer patients improves tumor Ki-67 expression, serum cytokine levels, and PBMCs transcriptome. <i>Brain, Behavior, and Immunity</i> , 2018 , 73, 294-309	16.6	40
209	Role of Platelet-Derived Tgf β in the Progression of Ovarian Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 5611-5621	12.9	39

208	Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy. <i>Oncotarget</i> , 2017 , 8, 96496-96505	3.3	39
207	A-to-I miR-378a-3p editing can prevent melanoma progression via regulation of PARVA expression. <i>Nature Communications</i> , 2018 , 9, 461	17.4	39
206	miR-509-3p is clinically significant and strongly attenuates cellular migration and multi-cellular spheroids in ovarian cancer. <i>Oncotarget</i> , 2016 , 7, 25930-48	3.3	39
205	Antagonism of tumoral prolactin receptor promotes autophagy-related cell death. <i>Cell Reports</i> , 2014 , 7, 488-500	10.6	38
204	Overexpression of enhancer of zeste homolog 2 (EZH2) and focal adhesion kinase (FAK) in high grade endometrial carcinoma. <i>Gynecologic Oncology</i> , 2013 , 128, 344-8	4.9	38
203	TFEB ameliorates the impairment of the autophagy-lysosome pathway in neurons induced by doxorubicin. <i>Aging</i> , 2016 , 8, 3507-3519	5.6	38
202	Ovarian cancer cell-derived lysophosphatidic acid induces glycolytic shift and cancer-associated fibroblast-phenotype in normal and peritumoral fibroblasts. <i>Cancer Letters</i> , 2019 , 442, 464-474	9.9	38
201	STAMP2 increases oxidative stress and is critical for prostate cancer. <i>EMBO Molecular Medicine</i> , 2015 , 7, 315-31	12	37
200	Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer. <i>Drug Delivery</i> , 2018 , 25, 1394-1402	7	36
199	miRNA551b-3p Activates an Oncostatin Signaling Module for the Progression of Triple-Negative Breast Cancer. <i>Cell Reports</i> , 2019 , 29, 4389-4406.e10	10.6	36
198	Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma. <i>European Journal of Cancer</i> , 2015 , 51, 1978-88	7.5	35
197	Perioperative beta-blocker use and survival in lung cancer patients. <i>Journal of Clinical Anesthesia</i> , 2014 , 26, 106-17	1.9	35
196	Depression and risk of epithelial ovarian cancer: Results from two large prospective cohort studies. <i>Gynecologic Oncology</i> , 2015 , 139, 481-6	4.9	34
195	Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancers. <i>Cancer Cell</i> , 2014 , 26, 863-879	24.3	34
194	The role of tumor microenvironment in resistance to anti-angiogenic therapy. <i>F1000Research</i> , 2018 , 7, 326	3.6	34
193	Focal adhesion kinase: an alternative focus for anti-angiogenesis therapy in ovarian cancer. <i>Cancer Biology and Therapy</i> , 2014 , 15, 919-29	4.6	33
192	Copper-64 Labeled PEGylated Exosomes for In Vivo Positron Emission Tomography and Enhanced Tumor Retention. <i>Bioconjugate Chemistry</i> , 2019 , 30, 2675-2683	6.3	32
191	HN1L Promotes Triple-Negative Breast Cancer Stem Cells through LEPR-STAT3 Pathway. <i>Stem Cell Reports</i> , 2018 , 10, 212-227	8	32

190	Role of Increased n-acetylaspartate Levels in Cancer. <i>Journal of the National Cancer Institute</i> , 2016 , 108, djv426	9.7	32
189	GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma. <i>Cellular Signalling</i> , 2020 , 68, 109539	4.9	32
188	Inhibition Synergistically Enhances the Effects of Magnetic Fluid Hyperthermia in Ovarian Cancer. <i>Molecular Cancer Therapeutics</i> , 2017 , 16, 966-976	6.1	31
187	Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation. <i>Nature Communications</i> , 2018 , 9, 476	17.4	31
186	Stress, inflammation, and eicosanoids: an emerging perspective. <i>Cancer and Metastasis Reviews</i> , 2018 , 37, 203-211	9.6	31
185	Significance of monocyte counts on tumor characteristics and survival outcome of women with endometrial cancer. <i>Gynecologic Oncology</i> , 2015 , 138, 332-8	4.9	31
184	Placenta-derived extracellular vesicles induce preeclampsia in mouse models. <i>Haematologica</i> , 2020 , 105, 1686-1694	6.6	31
183	Antitumor and Antiangiogenic Effects of Aspirin-PC in Ovarian Cancer. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 2894-2904	6.1	30
182	Geometrical confinement of Gd(DOTA) molecules within mesoporous silicon nanoconstructs for MR imaging of cancer. <i>Cancer Letters</i> , 2014 , 352, 97-101	9.9	30
181	DLL4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 1344-52	6.1	30
180	p63/DGCR8-Dependent MicroRNAs Mediate Therapeutic Efficacy of HDAC Inhibitors in Cancer. <i>Cancer Cell</i> , 2016 , 29, 874-888	24.3	29
179	Identifying and targeting angiogenesis-related microRNAs in ovarian cancer. <i>Oncogene</i> , 2019 , 38, 6095-6108	6.8	29
178	Low-grade serous ovarian cancer: State of the science. <i>Gynecologic Oncology</i> , 2020 , 156, 715-725	4.9	28
177	Diurnal cortisol rhythms, fatigue and psychosocial factors in five-year survivors of ovarian cancer. <i>Psychoneuroendocrinology</i> , 2017 , 84, 139-142	5	28
176	Coevolution of neoplastic epithelial cells and multilineage stroma via polyploid giant cells during immortalization and transformation of mullerian epithelial cells. <i>Genes and Cancer</i> , 2016 , 7, 60-72	2.9	28
175	Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer. <i>Cell Reports</i> , 2020 , 31, 107502	10.6	28
174	Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma. <i>JAMA Oncology</i> , 2015 , 1, 486-94	13.4	27
173	XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A. <i>Clinical Cancer Research</i> , 2015 , 21, 3286-97	12.9	27

172	Chromosomal Instability in Tumor Initiation and Development. <i>Cancer Research</i> , 2019 , 79, 3995-4002	10.1	27
171	Kallikrein family proteases KLK6 and KLK7 are potential early detection and diagnostic biomarkers for serous and papillary serous ovarian cancer subtypes. <i>Journal of Ovarian Research</i> , 2014 , 7, 109	5.5	27
170	Clodronate inhibits tumor angiogenesis in mouse models of ovarian cancer. <i>Cancer Biology and Therapy</i> , 2014 , 15, 1061-7	4.6	27
169	Peroxisomes contribute to oxidative stress in neurons during doxorubicin-based chemotherapy. <i>Molecular and Cellular Neurosciences</i> , 2018 , 86, 65-71	4.8	27
168	Aspirin use and endometrial cancer risk and survival. <i>Gynecologic Oncology</i> , 2018 , 148, 222-232	4.9	27
167	Platelet-derived growth factor receptor alpha (PDGFR α) targeting and relevant biomarkers in ovarian carcinoma. <i>Gynecologic Oncology</i> , 2014 , 132, 166-75	4.9	26
166	BRCA2 inhibition enhances cisplatin-mediated alterations in tumor cell proliferation, metabolism, and metastasis. <i>Molecular Oncology</i> , 2014 , 8, 1429-40	7.9	26
165	State of the science: Emerging therapeutic strategies for targeting angiogenesis in ovarian cancer. <i>Gynecologic Oncology</i> , 2015 , 138, 223-6	4.9	25
164	Quality of life among long-term survivors of advanced stage ovarian cancer: A cross-sectional approach. <i>Gynecologic Oncology</i> , 2017 , 146, 101-108	4.9	24
163	Copy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancer. <i>Gynecologic Oncology</i> , 2016 , 141, 57-64	4.9	24
162	Stress influences on anoikis. <i>Cancer Prevention Research</i> , 2011 , 4, 481-5	3.2	24
161	Ferroptosis as a mechanism to mediate p53 function in tumor radiosensitivity. <i>Oncogene</i> , 2021 , 40, 3533-3547	3.5	24
160	Thrombosis in Cancer: Research Priorities Identified by a National Cancer Institute/National Heart, Lung, and Blood Institute Strategic Working Group. <i>Cancer Research</i> , 2016 , 76, 3671-5	10.1	23
159	Differential Effects of EGFL6 on Tumor versus Wound Angiogenesis. <i>Cell Reports</i> , 2017 , 21, 2785-2795	10.6	23
158	Metronomic docetaxel in PRINT nanoparticles and EZH2 silencing have synergistic antitumor effect in ovarian cancer. <i>Molecular Cancer Therapeutics</i> , 2014 , 13, 1750-7	6.1	23
157	Toll-like receptor 3-induced immune response by poly(d,l-lactide-co-glycolide) nanoparticles for dendritic cell-based cancer immunotherapy. <i>International Journal of Nanomedicine</i> , 2016 , 11, 5729-5742	7.3	23
156	Lipid profile of platelets and platelet-derived microparticles in ovarian cancer. <i>BBA Clinical</i> , 2016 , 6, 76-81		23
155	ZRANB1 Is an EZH2 Deubiquitinase and a Potential Therapeutic Target in Breast Cancer. <i>Cell Reports</i> , 2018 , 23, 823-837	10.6	22

154	Linalool-Incorporated Nanoparticles as a Novel Anticancer Agent for Epithelial Ovarian Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 618-27	6.1	22
153	Prospective Validation of an Ex Vivo, Patient-Derived 3D Spheroid Model for Response Predictions in Newly Diagnosed Ovarian Cancer. <i>Scientific Reports</i> , 2019 , 9, 11153	4.9	22
152	Role of hysterectomy and lymphadenectomy in the management of early-stage borderline ovarian tumors. <i>Gynecologic Oncology</i> , 2017 , 144, 496-502	4.9	21
151	Developing hyperpolarized silicon particles for in vivo MRI targeting of ovarian cancer. <i>Journal of Medical Imaging</i> , 2016 , 3, 036001	2.6	21
150	Bisphosphonates inhibit stellate cell activity and enhance antitumor effects of nanoparticle albumin-bound paclitaxel in pancreatic ductal adenocarcinoma. <i>Molecular Cancer Therapeutics</i> , 2014 , 13, 2583-94	6.1	21
149	Highly heterogeneous genomic landscape of uterine leiomyomas by whole exome sequencing and genome-wide arrays. <i>Fertility and Sterility</i> , 2017 , 107, 457-466.e9	4.8	21
148	Biobehavioral modulation of the exosome transcriptome in ovarian carcinoma. <i>Cancer</i> , 2018 , 124, 580-586	6.4	21
147	Endothelial cell malignancies: new insights from the laboratory and clinic. <i>Npj Precision Oncology</i> , 2017 , 1, 11	9.8	20
146	PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis. <i>EBioMedicine</i> , 2019 , 40, 290-304	8.8	20
145	Trends of low-grade serous ovarian carcinoma in the United States. <i>Journal of Gynecologic Oncology</i> , 2018 , 29, e15	4	19
144	Pan-cancer genomic analysis links 3QTR DNA methylation with increased gene expression in T cells. <i>EBioMedicine</i> , 2019 , 43, 127-137	8.8	18
143	CDK5 Regulates Paclitaxel Sensitivity in Ovarian Cancer Cells by Modulating AKT Activation, p21Cip1- and p27Kip1-Mediated G1 Cell Cycle Arrest and Apoptosis. <i>PLoS ONE</i> , 2015 , 10, e0131833	3.7	18
142	Hypertension, use of antihypertensive medications, and risk of epithelial ovarian cancer. <i>International Journal of Cancer</i> , 2016 , 139, 291-9	7.5	18
141	Uterine carcinosarcoma: Contemporary clinical summary, molecular updates, and future research opportunity. <i>Gynecologic Oncology</i> , 2021 , 160, 586-601	4.9	18
140	Role of CTGF in Sensitivity to Hyperthermia in Ovarian and Uterine Cancers. <i>Cell Reports</i> , 2016 , 17, 1621-1631	6.3	17
139	Defining Survivorship Trajectories Across Patients With Solid Tumors: An Evidence-Based Approach. <i>JAMA Oncology</i> , 2018 , 4, 1519-1526	13.4	17
138	Precision Nanomedicine Using Dual PET and MR Temperature Imaging-Guided Photothermal Therapy. <i>Journal of Nuclear Medicine</i> , 2016 , 57, 1778-1783	8.9	16
137	Novel modification of the vertical rectus abdominis myocutaneous flap for neovagina creation. <i>Obstetrics and Gynecology</i> , 2005 , 105, 514-8	4.9	16

136	EGFL6 promotes breast cancer by simultaneously enhancing cancer cell metastasis and stimulating tumor angiogenesis. <i>Oncogene</i> , 2019 , 38, 2123-2134	9.2	16
135	Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy. <i>Therapeutic Advances in Medical Oncology</i> , 2018 , 10, 1758835918778483	5.4	15
134	Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial. <i>Clinical Cancer Research</i> , 2004 , 10, 6080-5 ^{12.9}	12.9	15
133	Pan-cancer clinical and molecular analysis of racial disparities. <i>Cancer</i> , 2020 , 126, 800-807	6.4	15
132	Minimally Invasive Surgery and Risk of Capsule Rupture for Women With Early-Stage Ovarian Cancer. <i>JAMA Oncology</i> , 2020 , 6, 1110-1113	13.4	14
131	Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial. <i>Gynecologic Oncology</i> , 2020 , 157, 386-391	4.9	14
130	Association of Ovarian Tumor α -Adrenergic Receptor Status with Ovarian Cancer Risk Factors and Survival. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016 , 25, 1587-1594	4	14
129	The rise of genomic profiling in ovarian cancer. <i>Expert Review of Molecular Diagnostics</i> , 2016 , 16, 1337-1358	13.8	14
128	DNA methylation signatures and coagulation factors in the peripheral blood leucocytes of epithelial ovarian cancer. <i>Carcinogenesis</i> , 2017 , 38, 797-805	4.6	14
127	6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase-2 Regulates TP53-Dependent Paclitaxel Sensitivity in Ovarian and Breast Cancers. <i>Clinical Cancer Research</i> , 2019 , 25, 5702-5716	12.9	14
126	Bioactive lipid metabolism in platelet "first responder" and cancer biology. <i>Cancer and Metastasis Reviews</i> , 2018 , 37, 439-454	9.6	13
125	Prospective pilot trial with combination of propranolol with chemotherapy in patients with epithelial ovarian cancer and evaluation on circulating immune cell gene expression. <i>Gynecologic Oncology</i> , 2019 , 154, 524-530	4.9	13
124	Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2017 , 147, 41-46	4.9	13
123	Biologic effects of platelet-derived growth factor receptor β blockade in uterine cancer. <i>Clinical Cancer Research</i> , 2014 , 20, 2740-50	12.9	13
122	p53 null mutations are associated with a telomerase negative phenotype in ovarian carcinoma. <i>Cancer Biology and Therapy</i> , 2002 , 1, 511-7	4.6	13
121	ADH1B promotes mesothelial clearance and ovarian cancer infiltration. <i>Oncotarget</i> , 2018 , 9, 25115-25125 ^{3.3}	3.3	13
120	Platelets are not hyperreactive in patients with ovarian cancer. <i>Platelets</i> , 2016 , 27, 716-718	3.6	13
119	Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options. <i>Oncotarget</i> , 2019 , 10, 3533-3546 ^{3.3}	3.3	12

118	MIIP remodels Rac1-mediated cytoskeleton structure in suppression of endometrial cancer metastasis. <i>Journal of Hematology and Oncology</i> , 2016 , 9, 112	22.4	12
117	Prediction of anti-angiogenesis escape. <i>Gynecologic Oncology</i> , 2016 , 141, 80-5	4.9	12
116	Survival outcome of stage I ovarian clear cell carcinoma with lympho-vascular space invasion. <i>Gynecologic Oncology</i> , 2015 , 136, 198-204	4.9	12
115	Characterization of and isolation methods for plant leaf nanovesicles and small extracellular vesicles. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2020 , 29, 102271	6	12
114	OvCa-Chip microsystem recreates vascular endothelium-mediated platelet extravasation in ovarian cancer. <i>Blood Advances</i> , 2020 , 4, 3329-3342	7.8	12
113	Concordance of a laparoscopic scoring algorithm with primary surgery findings in advanced stage ovarian cancer. <i>Gynecologic Oncology</i> , 2018 , 151, 428-432	4.9	12
112	Activating p53 family member TAp63: A novel therapeutic strategy for targeting p53-altered tumors. <i>Cancer</i> , 2019 , 125, 2409-2422	6.4	11
111	PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 1466-1475	6.1	11
110	A small amount of cyclooxygenase 2 (COX2) is constitutively expressed in platelets. <i>Platelets</i> , 2017 , 28, 99-102	3.6	11
109	Predictors of survival trajectories among women with epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2020 , 156, 459-466	4.9	11
108	Mucinous borderline ovarian tumor versus invasive well-differentiated mucinous ovarian cancer: Difference in characteristics and outcomes. <i>Gynecologic Oncology</i> , 2019 , 153, 230-237	4.9	11
107	Perineural invasion (PNI) in vulvar carcinoma: A review of 421 cases. <i>Gynecologic Oncology</i> , 2019 , 152, 101-105	4.9	11
106	/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer. <i>Molecular Cancer Therapeutics</i> , 2019 , 18, 162-172	6.1	11
105	Quaking orchestrates a post-transcriptional regulatory network of endothelial cell cycle progression critical to angiogenesis and metastasis. <i>Oncogene</i> , 2019 , 38, 5191-5210	9.2	10
104	Life stress as a risk factor for sustained anxiety and cortisol dysregulation during the first year of survivorship in ovarian cancer. <i>Cancer</i> , 2018 , 124, 3401-3408	6.4	10
103	Eudaimonic well-being and tumor norepinephrine in patients with epithelial ovarian cancer. <i>Cancer</i> , 2015 , 121, 3543-50	6.4	10
102	Clinical and biological significance of expression in endometrial cancer. <i>Cancer Biology and Therapy</i> , 2020 , 21, 147-156	4.6	10
101	Clinically translatable quantitative molecular photoacoustic imaging with liposome-encapsulated ICG J-aggregates. <i>Nature Communications</i> , 2021 , 12, 5410	17.4	10

100	GnRH-R-Targeted Lytic Peptide Sensitizes Wild-type Ovarian Cancer to PARP Inhibition. <i>Molecular Cancer Therapeutics</i> , 2019 , 18, 969-979	6.1	9
99	Minimally invasive surgery for early-stage ovarian cancer: Association between hospital surgical volume and short-term perioperative outcomes. <i>Gynecologic Oncology</i> , 2020 , 158, 59-65	4.9	9
98	Molecular Pathways and Targeted Therapies for Malignant Ovarian Germ Cell Tumors and Sex Cord-Stromal Tumors: A Contemporary Review. <i>Cancers</i> , 2020 , 12,	6.6	9
97	Ionizing Radiation Induces Endothelial Inflammation and Apoptosis via p90RSK-Mediated ERK5 S496 Phosphorylation. <i>Frontiers in Cardiovascular Medicine</i> , 2018 , 5, 23	5.4	9
96	Convergence of nanotechnology and cancer prevention: are we there yet?. <i>Cancer Prevention Research</i> , 2014 , 7, 973-92	3.2	9
95	Targeting the centriolar replication factor STIL synergizes with DNA damaging agents for treatment of ovarian cancer. <i>Oncotarget</i> , 2017 , 8, 27380-27392	3.3	9
94	Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience. <i>Oncotarget</i> , 2016 , 7, 35132-43	3.3	9
93	Long non-coding RNAs in ovarian cancer: expression profile and functional spectrum. <i>RNA Biology</i> , 2020 , 17, 1523-1534	4.8	9
92	Targeting progesterone signaling prevents metastatic ovarian cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 31993-32004	11.5	9
91	Pharmacogenomic analysis of patient-derived tumor cells in gynecologic cancers. <i>Genome Biology</i> , 2019 , 20, 253	18.3	9
90	Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 2677-86	6.1	8
89	Pelvic fractures and changes in bone mineral density after radiotherapy for cervical, endometrial, and vaginal cancer: A prospective study of 239 women. <i>Cancer</i> , 2020 , 126, 2607-2613	6.4	8
88	Induction of antitumor immunity in mice by the combination of nanoparticle-based photothermolysis and anti-PD-1 checkpoint inhibition. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2020 , 25, 102169	6	8
87	Assessment of In Vivo siRNA Delivery in Cancer Mouse Models. <i>Methods in Molecular Biology</i> , 2016 , 1402, 189-197	1.4	8
86	MIIP haploinsufficiency induces chromosomal instability and promotes tumour progression in colorectal cancer. <i>Journal of Pathology</i> , 2017 , 241, 67-79	9.4	8
85	Gain-of-function p53 protein transferred via small extracellular vesicles promotes conversion of fibroblasts to a cancer-associated phenotype. <i>Cell Reports</i> , 2021 , 34, 108726	10.6	8
84	Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	7
83	Oxytocin in the tumor microenvironment is associated with lower inflammation and longer survival in advanced epithelial ovarian cancer patients. <i>Psychoneuroendocrinology</i> , 2019 , 106, 244-251	5	7

82	Human tumor microenvironment chip evaluates the consequences of platelet extravasation and combinatorial antitumor-antiplatelet therapy in ovarian cancer. <i>Science Advances</i> , 2021 , 7,	14.3	7
81	Tumor core biopsies adequately represent immune microenvironment of high-grade serous carcinoma. <i>Scientific Reports</i> , 2019 , 9, 17589	4.9	7
80	Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4. <i>Molecular Cancer Therapeutics</i> , 2019 , 18, 421-436	6.1	7
79	The hidden role of paxillin: localization to nucleus promotes tumor angiogenesis. <i>Oncogene</i> , 2021 , 40, 384-395	9.2	7
78	Delineation of retroperitoneal metastatic lymph nodes in ovarian cancer with near-infrared fluorescence imaging. <i>Oncology Letters</i> , 2017 , 14, 2869-2877	2.6	6
77	Fundamental Principles of Cancer Biology: Does it have relevance to the perioperative period?. <i>Current Anesthesiology Reports</i> , 2015 , 5, 250-256	1	6
76	Isolation of Extracellular RNA from Serum/Plasma. <i>Methods in Molecular Biology</i> , 2018 , 1740, 43-57	1.4	6
75	ADAMTS16 mutations sensitize ovarian cancer cells to platinum-based chemotherapy. <i>Oncotarget</i> , 2017 , 8, 88410-88420	3.3	6
74	Reciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2. <i>Oncotarget</i> , 2016 , 7, 20825-39	3.3	6
73	Oncolytic HSV Therapy Modulates Vesicular Trafficking Inducing Cisplatin Sensitivity and Antitumor Immunity. <i>Clinical Cancer Research</i> , 2021 , 27, 542-553	12.9	6
72	Biobehavioral and neuroendocrine correlates of antioxidant enzyme activity in ovarian carcinoma. <i>Brain, Behavior, and Immunity</i> , 2015 , 50, 58-62	16.6	5
71	Retraction Note: miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2. <i>Nature</i> , 2020 , 582, 134	50.4	5
70	Role of Micro-RNA for Pain After Surgery: Narrative Review of Animal and Human Studies. <i>Anesthesia and Analgesia</i> , 2020 , 130, 1638-1652	3.9	5
69	Evolving population-based statistics for rare epithelial ovarian cancers. <i>Gynecologic Oncology</i> , 2020 , 157, 3-11	4.9	5
68	Profiling Long Noncoding RNA Expression Using Custom-Designed Microarray. <i>Methods in Molecular Biology</i> , 2016 , 1402, 33-41	1.4	5
67	Sustained Adrenergic Activation of YAP1 Induces Anoikis Resistance in Cervical Cancer Cells. <i>IScience</i> , 2020 , 23, 101289	6.1	5
66	Epithelial-mesenchymal transition polarization in ovarian carcinomas from patients with high social isolation. <i>Cancer</i> , 2020 , 126, 4407-4413	6.4	5
65	Clinical significance of homologous recombination deficiency score testing in endometrial Cancer. <i>Gynecologic Oncology</i> , 2021 , 160, 777-785	4.9	5

64	Significance of lymph node ratio on survival of women with borderline ovarian tumors. <i>Archives of Gynecology and Obstetrics</i> , 2020 , 301, 1289-1298	2.5	5
63	Emerging Trends in Neoadjuvant Chemotherapy for Ovarian Cancer. <i>Cancers</i> , 2021 , 13,	6.6	5
62	Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 6354-6365	12.9	5
61	Targeting Forward and Reverse EphB4/EFNB2 Signaling by a Peptide with Dual Functions. <i>Scientific Reports</i> , 2020 , 10, 520	4.9	4
60	The Role of Angiogenesis in Cancer 2015 , 64-71		4
59	Tumor T1 Relaxation Time for Assessing Response to Bevacizumab Anti-Angiogenic Therapy in a Mouse Ovarian Cancer Model. <i>PLoS ONE</i> , 2015 , 10, e0131095	3.7	4
58	RNA-binding protein FXR1 drives cMYC translation by recruiting eIF4F complex to the translation start site. <i>Cell Reports</i> , 2021 , 37, 109934	10.6	4
57	The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance. <i>Gynecologic Oncology</i> , 2020 , 158, 653-658	4.9	4
56	Enhanced Immunotherapy with LHRH-R Targeted Lytic Peptide in Ovarian Cancer. <i>Molecular Cancer Therapeutics</i> , 2020 , 19, 2396-2406	6.1	4
55	Mitochondria in epithelial ovarian carcinoma exhibit abnormal phenotypes and blunted associations with biobehavioral factors. <i>Scientific Reports</i> , 2021 , 11, 11595	4.9	4
54	Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review. <i>Gynecologic Oncology</i> , 2021 , 162, 482-495	4.9	4
53	Diagnosis-shift between low-grade serous ovarian cancer and serous borderline ovarian tumor: A population-based study. <i>Gynecologic Oncology</i> , 2020 , 157, 21-28	4.9	3
52	Association of biobehavioral factors with non-coding RNAs in cervical cancer. <i>BioScience Trends</i> , 2018 , 12, 24-31	9.9	3
51	Reply to beta blockers in epithelial ovarian cancer and beta-blockers and improved survival from ovarian cancer: New miracle treatment or another case of immortal person-time bias?. <i>Cancer</i> , 2016 , 122, 325-6	6.4	3
50	Genome-wide perturbations by miRNAs map onto functional cellular pathways, identifying regulators of chromatin modifiers. <i>Npj Systems Biology and Applications</i> , 2015 , 1, 15001	5	3
49	Blockade of the Short Form of Prolactin Receptor Induces FOXO3a/EIF-4EBP1-Mediated Cell Death in Uterine Cancer. <i>Molecular Cancer Therapeutics</i> , 2020 , 19, 1943-1954	6.1	3
48	The effect of platelet G proteins on platelet extravasation and tumor growth in the murine model of ovarian cancer. <i>Blood Advances</i> , 2021 , 5, 1947-1951	7.8	3
47	CD8 T cells inhibit metastasis and CXCL4 regulates its function. <i>British Journal of Cancer</i> , 2021 , 125, 176-189	8.9	3

46	Combined VEGFR and MAPK pathway inhibition in angiosarcoma. <i>Scientific Reports</i> , 2021 , 11, 9362	4.9	3
45	Positive Psychosocial Factors and Oxytocin in the Ovarian Tumor Microenvironment. <i>Psychosomatic Medicine</i> , 2021 , 83, 417-422	3.7	3
44	Extensive three-dimensional intratumor proteomic heterogeneity revealed by multiregion sampling in high-grade serous ovarian tumor specimens. <i>iScience</i> , 2021 , 24, 102757	6.1	3
43	Possible candidate population for neoadjuvant chemotherapy in women with advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2021 , 160, 32-39	4.9	3
42	The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial. <i>Investigational New Drugs</i> , 2021 , 39, 829-835	4.3	3
41	PRKAR1B-AS2 Long Noncoding RNA Promotes Tumorigenesis, Survival, and Chemoresistance via the PI3K/AKT/mTOR Pathway. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	3
40	Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer. <i>Molecular Cancer Therapeutics</i> , 2018 , 17, 464-473	6.1	3
39	Expression of B7-H4 and IDO1 is associated with drug resistance and poor prognosis in high-grade serous ovarian carcinomas. <i>Human Pathology</i> , 2021 , 113, 20-27	3.7	3
38	IL-6 promotes drug resistance through formation of polyploid giant cancer cells and stromal fibroblast reprogramming. <i>Oncogenesis</i> , 2021 , 10, 65	6.6	3
37	NRG1/ERBB3 Pathway Activation Induces Acquired Resistance to XPO1 Inhibitors. <i>Molecular Cancer Therapeutics</i> , 2020 , 19, 1727-1735	6.1	2
36	Of vascular defense, hemostasis, cancer, and platelet biology: an evolutionary perspective.. <i>Cancer and Metastasis Reviews</i> , 2022 , 41, 147	9.6	2
35	Endothelial p130cas confers resistance to anti-angiogenesis therapy.. <i>Cell Reports</i> , 2022 , 38, 110301	10.6	2
34	Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens. <i>JCI Insight</i> , 2018 , 3,	9.9	2
33	NO-dependent attenuation of TPA-induced immunoinflammatory skin changes in Balb/c mice by pindolol, heptaminol or ATRA, but not by verapamil. <i>Oncotarget</i> , 2016 , 7, 47576-47585	3.3	2
32	Therapeutic efficacy of liposomal Grb2 antisense oligodeoxynucleotide (L-Grb2) in preclinical models of ovarian and uterine cancer. <i>Oncotarget</i> , 2020 , 11, 2819-2833	3.3	2
31	The life cycle of polyploid giant cancer cells and dormancy in cancer: Opportunities for novel therapeutic interventions. <i>Seminars in Cancer Biology</i> , 2021 ,	12.7	2
30	Dasatinib, paclitaxel, and carboplatin in women with advanced-stage or recurrent endometrial cancer: A pilot clinical and translational study. <i>Gynecologic Oncology</i> , 2021 , 161, 104-112	4.9	2
29	Gene Body Methylation of the Lymphocyte-Specific Gene Results in Its Overexpression and Regulates Cancer mTOR Signaling. <i>Molecular Cancer Research</i> , 2021 , 19, 1917-1928	6.6	2

28	CD63-mediated cloaking of VEGF in small extracellular vesicles contributes to anti-VEGF therapy resistance. <i>Cell Reports</i> , 2021 , 36, 109549	10.6	2
27	Correlation of surgeon radiology assessment with laparoscopic disease site scoring in patients with advanced ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2021 , 31, 92-97	3.5	1
26	Can stress promote the pathophysiology of brain metastases? A critical review of biobehavioral mechanisms. <i>Brain, Behavior, and Immunity</i> , 2020 , 87, 860-880	16.6	1
25	A Solution to the Dilution: The Role for Biomarkers in Advanced Ovarian Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 9-10	12.9	1
24	Joint IARC/NCI International Cancer Seminar Series Report: expert consensus on future directions for ovarian carcinoma research. <i>Carcinogenesis</i> , 2021 , 42, 785-793	4.6	1
23	Timing of surgery in patients with partial response or stable disease after neoadjuvant chemotherapy for advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2021 , 161, 660-667	4.9	1
22	Distinct T cell receptor repertoire diversity of clinically defined high-grade serous ovarian cancer treatment subgroups. <i>IScience</i> , 2021 , 24, 102053	6.1	1
21	A Modified 2 Tier Chemotherapy Response Score (CRS) and Other Histopathologic Features for Predicting Outcomes of Patients with Advanced Extruterine High-Grade Serous Carcinoma after Neoadjuvant Chemotherapy. <i>Cancers</i> , 2021 , 13,	6.6	1
20	The Provocative Roles of Platelets in Liver Disease and Cancer. <i>Frontiers in Oncology</i> , 2021 , 11, 643815	5.3	1
19	Rural residence is related to shorter survival in epithelial ovarian cancer patients. <i>Gynecologic Oncology</i> , 2021 , 163, 22-28	4.9	1
18	Immune microenvironment composition in high-grade serous ovarian cancers based on BRCA mutational status. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021 , 147, 3545-3555	4.9	1
17	Spatially resolved transcriptomics of high-grade serous ovarian carcinoma.. <i>IScience</i> , 2022 , 25, 103923	6.1	1
16	Platelets Increase the Expression of PD-L1 in Ovarian Cancer. <i>Cancers</i> , 2022 , 14, 2498	6.6	1
15	Targeting CCR2 macrophages with BET inhibitor overcomes adaptive resistance to anti-VEGF therapy in ovarian cancer.. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022 , 148, 803	4.9	0
14	Chronic difficulties are associated with poorer psychosocial functioning in the first year post-diagnosis in epithelial ovarian cancer patients. <i>Psycho-Oncology</i> , 2021 , 30, 954-961	3.9	0
13	Cost-effectiveness of laparoscopic disease assessment in patients with newly diagnosed advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2021 , 161, 56-62	4.9	0
12	A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice. <i>Gynecologic Oncology</i> , 2018 , 151, 374-380	4.9	0
11	Factors associated with response to neoadjuvant chemotherapy in advanced stage ovarian cancer. <i>Gynecologic Oncology</i> , 2021 , 162, 65-71	4.9	0

10	MEK inhibition overcomes resistance to EphA2-targeted therapy in uterine cancer. <i>Gynecologic Oncology</i> , 2021 , 163, 181-190	4.9	○
9	Antihypertensive medication use and ovarian cancer survival. <i>Gynecologic Oncology</i> , 2021 , 163, 342-347	4.9	○
8	Rational Combination of CRM1 Inhibitor Selinexor and Olaparib Shows Synergy in Ovarian Cancer Cell Lines and Mouse Models. <i>Molecular Cancer Therapeutics</i> , 2021 , 20, 2352-2361	6.1	○
7	Race-associated Molecular Changes in Gynecologic Malignancies. <i>Cancer Research Communications</i> , 2022 , 2, 99-109		○
6	RNAi in Cancer Therapy 2013 , 271-307		
5	Pathologic distribution at the time of interval tumor reductive surgery informs personalized surgery for high-grade ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2021 , 31, 232-237	3.5	
4	Attributions of survival and methods of coping of long-term ovarian cancer survivors: a qualitative study. <i>BMC Women's Health</i> , 2021 , 21, 376	2.9	
3	Platelet Function in Ovarian Cancer. <i>Blood</i> , 2015 , 126, 4656-4656	2.2	
2	Immunological consequences of ageing microvascular hemodynamic changes in view of cancer development and treatment. <i>Oncotarget</i> , 2017 , 8, 69047-69061	3.3	
1	Assessment of In Vivo siRNA Delivery in Cancer Mouse Models. <i>Methods in Molecular Biology</i> , 2021 , 2372, 157-168	1.4	